-
公开(公告)号：EP2842417B1
公开(公告)日：2018-03-14
申请号：EP13780731.9
申请日：2013-04-25
申请人： Tokyo Metropolitan Institute of Medical Science , Chugai Seiyaku Kabushiki Kaisha , Phoenixbio Co., Ltd.
发明人： KOHARA, Michinori , JISHAGE, Koichi , KAWASE, Yosuke , MUKAIDANI, Chise , OSHITA, Hiroki , HAMAMURA, Satoko
IPC分类号： C12N9/72 , C12N15/85 , A01K67/027 , G01N33/50
CPC分类号： A01K67/0275 , A01K67/0271 , A01K2207/12 , A01K2207/15 , A01K2217/052 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0337 , A01K2267/035 , C12N9/6462 , C12N15/8509 , C12N15/8775 , C12N2015/8581 , G01N33/5067 , G01N33/5088 , Y10T436/146666
摘要： The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of: (i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof; (ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo; (iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and (iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.
-
公开(公告)号：EP2842417A1
公开(公告)日：2015-03-04
申请号：EP13780731.9
申请日：2013-04-25
申请人： Tokyo Metropolitan Institute of Medical Science , Chugai Seiyaku Kabushiki Kaisha , Phoenixbio Co., Ltd.
发明人： KOHARA, Michinori , JISHAGE, Koichi , KAWASE, Yosuke , MUKAIDANI, Chise , OSHITA, Hiroki , HAMAMURA, Satoko
IPC分类号： A01K67/027 , G01N33/15 , G01N33/50 , C12N15/09
CPC分类号： A01K67/0275 , A01K67/0271 , A01K2207/12 , A01K2207/15 , A01K2217/052 , A01K2217/15 , A01K2217/206 , A01K2227/105 , A01K2267/0337 , A01K2267/035 , C12N9/6462 , C12N15/8509 , C12N15/8775 , C12N2015/8581 , G01N33/5067 , G01N33/5088 , Y10T436/146666
摘要： The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of:
(i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof;
(ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo;
(iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and
(iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.-
3.发明公开OLIGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING ACTIVITY OF HEPATITIS C VIRUS 审中-公开OLIGORIBONUKLEOTIDBZW. PEPTIDNUKLEINSÄUREZUR HEMMUNG DERAKTIVITÄTDES HEPATITIS-C-VIRUS
公开(公告)号：EP2368989A1
公开(公告)日：2011-09-28
申请号：EP09829126.3
申请日：2009-11-26
发明人： KOHARA, Michinori , SUDO, Masayuki
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/713 , A61K35/76 , A61K48/00 , A61P31/14 , A61P31/16 , A61P31/18
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/11
摘要： The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system.
摘要翻译： 本发明人着重于已被认为对HCV病毒RNA显示RNAi活性的siE序列，主要选择存在于IRES区域内的D5-50和D5-197区域，并进行分析。 结果，本发明人成功地鉴定了对丙型肝炎病毒RNA表现出更有效的RNAi活性的siRNA序列。 此外，证实siRNA在体内系统中对HCV繁殖具有显着的抑制作用。
-
4.发明公开OLIGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING ACTIVITY OF HEPATITIS C VIRUS 审中-公开核糖核苷酸或 肽核酸丙型肝炎病毒抑制活性
公开(公告)号：EP2368989A9
公开(公告)日：2012-02-29
申请号：EP09829126.3
申请日：2009-11-26
发明人： KOHARA, Michinori , SUDO, Masayuki
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/713 , A61K35/76 , A61K48/00 , A61P31/14 , A61P31/16 , A61P31/18
CPC分类号： C12N15/113 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2320/11
摘要： The present inventors focused on siE sequences that have been thought to show RNAi activity against HCV viral RNAs, and mainly selected the D5-50 and D5-197 regions present within the IRES region, and carried on the analysis. As a result, the present inventors successfully identified siRNA sequences that exhibit a more effective RNAi activity against hepatitis C virus RNAs. Furthermore, the siRNAs were demonstrated to have a significant inhibitory effect on HCV propagation in an in vivo system.
-
公开(公告)号：EP0919122A1
公开(公告)日：1999-06-02
申请号：EP97933015.6
申请日：1997-07-24
IPC分类号： A01K67/027
CPC分类号： C07K14/005 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0337 , C12N15/8509 , C12N2770/24222 , C12N2800/30
摘要： A hepatitis type C animal model into which cDNA derived from hepatitis C virus has been introduced. This animal model is useful for clarification of an onset mechanism of hepatitis C and as well as for development of means for treating the disease.
摘要翻译： 引入了丙型肝炎病毒cDNA的丙型肝炎动物模型。 该动物模型可用于澄清丙型肝炎的发病机制，以及用于治疗疾病的手段的开发。
-
6.发明公开POLYNUCLEOTIDE DERIVED FROM NOVEL HEPATITIS C VIRUS STRAIN AND USE THEREOF 审中-公开AUS EINEM NEUEN HEPATITIS-C-VIRENSTAMM GEWONNENES POLYNUKLEOTID UND VERWENDUNG DAVON
公开(公告)号：EP2471917A1
公开(公告)日：2012-07-04
申请号：EP10811924.9
申请日：2010-08-25
IPC分类号： C12N15/09 , A01K67/027 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12Q1/02 , G01N33/15 , G01N33/50
CPC分类号： C12Q1/707 , C12N7/00 , C12N2770/24221 , C12N2770/24222 , C12N2770/24243 , C12N2770/24251 , G01N2333/18 , G01N2500/10
摘要： A polynucleotide encoding the amino acid shown in SEQ ID NO:2 or SEQ ID NO: 5, or encoding an amino acid sequence having not less than 98% identity thereto; preferably a polynucleotide comprising replacement of the amino acid corresponding to glutamic acid at position 1202 of SEQ ID NO:2 (position 177 of SEQ ID NO:5) with glycine, replacement of the amino acid corresponding to glutamic acid at position 1056 (position 31 of SEQ ID NO:5) with valine, and replacement of the amino acid corresponding to alanine at position 2199 (position 1174 of SEQ ID NO:5) with threonine.
摘要翻译： 编码SEQ ID NO：2或SEQ ID NO：5所示氨基酸的多核苷酸，或编码与其同一性不少于98％的氨基酸序列; 优选包括将SEQ ID NO：2的第1202位（SEQ ID NO：5的第177位）与谷氨酸相对应的氨基酸的氨基酸与甘氨酸的取代相对应的位置1056处的谷氨酸的氨基酸（位置31 SEQ ID NO：5）与缬氨酸的氨基酸取代，并且用苏氨酸置换对应于位置2199（SEQ ID NO：5的位置1174）的丙氨酸。
-
公开(公告)号：EP2267120B1
公开(公告)日：2016-05-18
申请号：EP09717492.4
申请日：2009-03-06
申请人： Tokyo Metropolitan Institute of Medical Science , The Chemo-Sero-Therapeutic Research Institute
发明人： KOHARA, Michinori , MURAI, Fukashi
CPC分类号： C12N15/8636 , A01K67/0275 , A01K2217/15 , A01K2217/203 , A01K2267/0337 , A61K35/13 , A61K39/12 , A61K39/29 , A61K2039/525 , A61K2039/5256 , A61K2039/57 , C07K14/005 , C12N15/8509 , C12N2710/24143 , C12N2770/24222 , C12N2770/24234
-
公开(公告)号：EP3693006A1
公开(公告)日：2020-08-12
申请号：EP18864669.9
申请日：2018-10-04
申请人： Toko Yakuhin Kogyo Co., Ltd. , Tokyo Metropolitan Institute of Medical Science , Japan as Represented by Director-General of National Institute of Infectious Diseases , Kagoshima University , National University Corporation Ehime University
发明人： KAMISHITA, Taizou , MIYAZAKI, Takashi , KOHARA, Michinori , SANADA, Takahiro , HIASA, Yoichi , YOSHIDA, Osamu , KOHARA, Kyoko , HASEGAWA, Hideki
摘要： The present invention relates to a hepatitis B vaccine composition for spray-administration to nasal mucosa for preventing and treating hepatitis B, which comprises hepatitis B antigen and carboxy vinyl polymer.
-
公开(公告)号：EP3210995A1
公开(公告)日：2017-08-30
申请号：EP15852879.4
申请日：2015-10-23
摘要： Object of the present invention is to provide a hemagglutinin-binding peptide producing an anti-influenza virus effect higher than that of existing peptides. The present invention provides, for example, a hemagglutinin-binding peptide comprising a polypeptide having any of the following amino acid sequences (i) to (iv):
(i) Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His-Tyr-Thr-Val-Pro-Arg (SEQ ID NO:1);
(ii) Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser (SEQ ID NO: 2);
(iii) an amino acid sequence with deletions, additions, or substitutions of one or several amino acids in SEQ ID NO: 1 or 2; and
(iv) an amino acid sequence having 90% or more sequence identity to that of SEQ ID NO: 1 or 2.摘要翻译： 本发明的目的是提供一种产生比现有肽更高的抗流感病毒作用的血凝素结合肽。 例如，本发明提供了包含具有任何以下氨基酸序列（i）至（iv）的多肽的血细胞凝集素结合肽：（i）Thr-MeGly-Asp-MePhe-MePhe-Ser-MeSer-His -Tyr-Thr-Val-Pro-Arg（SEQ ID NO：1）; （ii）Arg-Val-Ser-MePhe-Thr-Tyr-MePhe-MeSer-Tyr-Thr-Pro-Ser（SEQ ID NO：2）。 （iii）在SEQ ID NO：1或2中具有一个或几个氨基酸缺失，添加或取代的氨基酸序列; 和（iv）与SEQ ID NO：1或2具有90％或更多序列同一性的氨基酸序列。
-
10.发明公开
公开(公告)号：EP3888677A1
公开(公告)日：2021-10-06
申请号：EP19884182.7
申请日：2019-11-14
发明人： YASUI, Fumihiko , KOHARA, Michinori , YAMAJI, Kenzaburo , ITOH, Yasushi , OGASAWARA, Kazumasa , ISHII, Koji
IPC分类号： A61K39/275 , A61P31/16 , A61K35/76 , C12N7/01 , C12N15/44
摘要： Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.023 秒)
